Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients
Table 3
Association of 17βHSD-1 promoter methylation with clinicopathological parameters.
Overall ()
%
17βHSD-1 methylation in normal tissues
17βHSD-1 methylation in cancer tissues
Methylated (38)
Unmethylated (2)
value
Methylated (39)
Unmethylated (1)
value
Freq.
(%)
Freq.
(%)
Freq.
(%)
Freq.
(%)
Age:
<50
10
25%
5
(29.4)
5
(21.7)
0.717
9
(23.1)
1
(100.0)
0.250
≥50
30
75%
12
(70.6)
18
(78.3)
30
(76.9)
0
(0.0)
Menopausal status:
Premenopause
7
17.5%
7
(18.4)
0
(0.0)
1.000
7
(17.9)
0
(0.0)
1.000
Postmenopause
33
82.5%
31
(81.6)
2
(100.0)
32
(82.1)
1
(100.0)
Age at menopause:
≤50
28
70.0%
26
(68.4)
2
(100.0)
0.637
27
(69.2)
1
(100.0)
1.000
>50
5
12.5%
5
(13.2)
0
(0.0)
5
(12.8)
0
(0.0)
Premenopausal
7
17.5%
7
(18.4)
0
(0.0)
7
(17.9)
0
(0.0)
Mean ± SD
49.2 ± 3.7
49.5 ± 3.4
44 ± 5.7
0.397
49.2 ± 3.7
45.0
0.242
Tumor size:
T1
4
10.0%
4
(10.5)
0
(0.0)
0.271
3
(7.7)
1
(100.0)
0.300
T2
28
70.0%
27
(71.1)
1
(50.0)
28
(71.8)
0
(0.0)
T3
4
10.0%
3
(7.9)
1
(50.0)
4
(10.3)
0
(0.0)
T4
4
10.0%
4
(10.5)
0
(0.0)
4
(10.3)
0
(0.0)
Lymph node status:
N0
11
27.5%
11
(28.9)
0
(0.0)
0.368
11
(28.2)
0
(0.0)
0.400
N1
8
20.0%
7
(18.4)
1
(50.0)
7
(17.9)
1
(100.0)
N2
13
32.5%
13
(34.2)
0
(0.0)
13
(33.3)
0
(0.0)
N3
8
20.0%
7
(18.4)
1
(50.0)
8
(20.5)
0
(0.0)
Clinical stage:
I
2
5.0%
2
(5.3)
0
(0.0)
0.327
2
(5.1)
0
(0.0)
0.675
IIA
10
25.0%
10
(26.3)
0
(0.0)
9
(23.1)
1
(100.0)
IIB
13
32.5%
13
(34.2)
0
(0.0)
13
(33.3)
0
(0.0)
IIIA
4
10.0%
3
(7.9)
1
(50.0)
4
(10.3)
0
(0.0)
IIIB
3
7.5%
3
(7.9)
0
(0.0)
3
(7.7)
0
(0.0)
IIIC
8
20.0%
7
(18.4)
1
(50.0)
8
(20.5)
0
(0.0)
Histological grade:
G1
3
7.5%
3
(7.9)
0
(0.0)
0.873
3
(7.7)
0
(0.0)
1.000
G2
30
75.0%
28
(73.7)
2
(100.0)
29
(74.4)
1
(100.0)
G3
3
7.5%
3
(7.9)
0
(0.0)
3
(7.7)
0
(0.0)
No grade
4
10.0%
4
(10.5)
0
(0.0)
4
(10.3)
0
(0.0)
Chi-square exact test is statistically significant at 95% confidence level.
